



Amvuttra in India

The CDSCO named-patient coordination pathway — indicative 2026

RARE DISEASE · HATTR POLYNEUROPATHY · ATTR-CM

The clinical situation

Amvuttra (vutrisiran) is a subcutaneous GalNAc-conjugated siRNA targeting hepatic TTR messenger RNA, FDA-approved for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) and for transthyretin amyloid cardiomyopathy (ATTR-CM). Manufactured by Alnylam. Administration is a 25 mg subcutaneous injection once every three months. Pre-treatment workup covers TTR genotype confirmation for hATTR, vitamin A supplementation counselling, baseline neurological or cardiac assessment, and ophthalmologic review per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist or cardiologist documents hATTR or ATTR-CM diagnosis, staging, genotype, and Amvuttra rationale.
- 2 Baseline workup.** TTR genotype, vitamin A supplementation counselling, cardiac and neurologic baseline, ophthalmology review per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, q3-month dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the pre-filled syringe; subcutaneous administration arranged with the treating physician.

Indicative economics

Reference US cash-pay range: USD 480,000–520,000 per year of Amvuttra (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Alnylam authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with TTR-genotype and vitamin A counselling annex. **Logistics.** Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through every three-month refill. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Amvuttra × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/amvuttra-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team